PTPRC and acute myeloid leukemia: We also highlight recent favorable results for 131I-anti-CD45 antibodies (131I-anti-CD45-apamistamab [Iomab-B]; Actinium Pharmaceuticals), which are currently being tested in a phase III trial on acute myeloid leukemia (AML) (20).